Year | Detail |
1941 |
Nihon Eisai Co. Ltd. is established in Saitama, eastern Japan. |
1944 |
Sakuragaoka Laboratory Co. Ltd. and Nihon Eisai Co. Ltd. merge under the name Nihon Eisai Co. Ltd. |
1950 |
Launched cardiotonic Neophyllin in Japan. |
1952 |
Nihon Eisai Co. Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets in Japan. |
1955 |
The company changes its name from Nihon Eisai Co. Ltd. to Eisai Co. Ltd. |
1961 |
Eisai opens its Taipei Office. |
1969 |
Youda Co. Ltd. is established as a pharmaceutical imports subsidiary in Taiwan. |
1970 |
PT Eisai Indonesia is established. |
1971 |
Toyoji opens the Naito Museum of Pharmaceutical Science and Industry. |
1974 |
Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. |
1977 |
Launched Naturally derived vitamin E product Juvelux. |
1981 |
Eisai U.S.A. Inc. is established. |
1982 |
The Tsukuba Research Laboratories open in Ibaraki, eastern Japan. |
1989 |
Eisai Machinery GmbH is established in Germany. |
1995 |
Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the U.S. |
1998 |
Aricept is launched in France. |
2004 |
Eisai Europe Ltd. is established. |
2008 |
Eisai acquires MGI Pharma Inc. |
2018 |
Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co. Inc. and Kenilworth. |
2020 |
Unlimit Health Limited is established in Shanghai, China. |
2022 |
Eisai Pharmaceuticals Africa (Pty) Ltd is established. |
2023 |
LEQEMBI is launched in Japan. |